HCW Biologics Inc. (HCWB) |
|
1.97 -0.005 (-0.25%)
|
05-16 01:16 |
|
Open: |
2.08 |
Pre. Close: |
1.975 |
|
High:
|
2.3899 |
Low:
|
1.9112 |
|
Volume:
|
49,376 |
Market Cap:
|
71(M) |
|
|
|
|
HCW Biologics Inc., a preclinical stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases. The company's lead products include HCW9218, which is an injectable immunotherapeutic for patients with pancreatic, ovarian, breast, prostate, and colorectal cancers, as well as pulmonary fibrosis; and HCW9302 for auto-immune diseases, such as alopecia areata and metabolic diseases. It also develops HCW9201, a cell-based therapy that is in Phase II clinical trials for the treatment of patients with relapsed/refractory acute myeloid leukemia; and HCW9206 for the treatment of acute myeloid leukemia. The company was incorporated in 2018 and is headquartered in Miramar, Florida. |
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
2.39 - 2.41 |
2.41 - 2.42 |
|
Low:
|
1.88 - 1.9 |
1.9 - 1.91 |
|
Close:
|
1.95 - 1.97 |
1.97 - 1.99 |
|
Technical analysis |
as of: 2022-05-13 4:38:43 PM |
|
Overall:
|
  |
| Stoxline posted a BUY today, upgraded from lower rating. Upward movement to be expected. |
| Target: |
Six months: 3.15  One year: 3.73 |
| Support: |
Support1: 1.89 Support2: 1.58 |
| Resistance: |
Resistance1: 2.7 Resistance2: 3.2 |
| Pivot: |
2.2 |
| Moving Average: |
MA(5): 2 MA(20): 2.31
MA(100): 2.33 MA(250): 0 |
| MACD: |
MACD(12,26): -0.2 Signal(9): -0.2 |
| Stochastic oscillator: |
%K(14,3): 11.1 %D(3): 8.5 |
| RSI: |
RSI(14): 30.1 |
| 52-week: |
High: 7.05 Low: 1.88 |
| Average Vol(K): |
3-Month: 32 (K) 10-Days: 17 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ HCWB ] has closed above bottom band by 15.4%. Bollinger Bands are 15.5% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Headline News |
Sun, 15 May 2022
Short Interest in HCW Biologics Inc. (NASDAQ:HCWB) Decreases By 32.5% - Defense World
Mon, 09 May 2022
Insiders might want to re-evaluate their US$6.9m stock purchase as HCW Biologics Inc. (NASDAQ:HCWB) drops to US$74m - Simply Wall St
Tue, 19 Apr 2022
HCW Biologics' CEO Hing C. Wong, Ph.D., to be Featured Speaker at the Third Annual ... - WDRB
Thu, 24 Mar 2022
HCW Biologics to Present at 2022 Virtual Growth Conference Sponsored by the Maxim Group and M-Vest - Yahoo Finance
Mon, 31 Jan 2022
Focused Wealth Management, Inc Buys PIMCO Active Bond ETF, iShares Core U.S. ... - Yahoo Finance
Thu, 20 Jan 2022
HCW Biologics Inc. Announces its Lead Product Candidate Shown to Augment Anti-Tumor Activity and Reduce Side Effects of Chemotherapy Regimens - GlobeNewswire
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Neutral |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Neutral |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
36 (M) |
| Shares Float |
12 (M) |
|
% Held by Insiders
|
75.1 (%) |
|
% Held by Institutions
|
0.5 (%) |
|
Shares Short
|
91 (K) |
|
Shares Short P.Month
|
94 (K) |
Stock Financials |
|
EPS
|
-0.74 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
1.5 |
|
Profit Margin (%)
|
-186.1 |
|
Operating Margin (%)
|
-199.9 |
|
Return on Assets (ttm)
|
0 |
|
Return on Equity (ttm)
|
0 |
|
Qtrly Rev. Growth
|
0 |
|
Gross Profit (p.s.)
|
0.11 |
|
Sales Per Share
|
0.11 |
|
EBITDA (p.s.)
|
-0.22 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
-11 (M) |
|
Levered Free Cash Flow
|
0 (M) |
Stock Valuations |
|
PE Ratio
|
-2.7 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
1.3 |
|
Price to Sales
|
17.16 |
|
Price to Cash Flow
|
-6.32 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
7 Binary Options
|
|
Your Ad Here
|
|
